Search Results
Nov 18, 2025, 12:00 ET MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
MLTX). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN MOONLAKE IMMUNOTHERAPEUTICS (MLTX), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE DECEMBER 15, 2025 (LEAD
More news about: Law Offices of Howard G. Smith
Nov 18, 2025, 09:00 ET MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact Levi & Korsinsky Before December 15, 2025 to Discuss Your Rights - MLTX
2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) of a class action securities lawsuit.
More news about: Levi & Korsinsky, LLP
Nov 17, 2025, 21:45 ET MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit
/PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline.
More news about: THE ROSEN LAW FIRM, P. A.
Nov 17, 2025, 09:16 ET MLTX DEADLINE REMINDER: Berger Montague Reminds MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors of Important Class Action Lawsuit Deadline
Berger Montague PC announces a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake" or the "Company") on behalf of investors who purchased MoonLake shares during the period of March 10, 2024 through September 29, 2025
More news about: Berger Montague
Nov 17, 2025, 08:45 ET MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact The Gross Law Firm Before December 15, 2025 to Discuss Your Rights - MLTX
Nov. 17, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX).
More news about: The Gross Law Firm
Nov 14, 2025, 12:00 ET MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
MLTX).
More news about: Glancy Prongay & Murray LLP
Nov 14, 2025, 09:41 ET Faruqi & Faruqi Reminds MoonLake Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 15, 2025 - MLTX
LLP, a leading national securities law firm, is investigating potential claims against Reuters Research Inc. ("MoonLake" or the "Company") (NASDAQ: MLTX) and reminds investors of the December 15, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been
More news about: Faruqi & Faruqi, LLP
Nov 14, 2025, 09:00 ET MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact Levi & Korsinsky Before December 15, 2025 to Discuss Your Rights - MLTX
2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) of a class action securities lawsuit.
More news about: Levi & Korsinsky, LLP
Nov 12, 2025, 21:18 ET MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit
York, N.Y., November 12, 2025. Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline.
More news about: THE ROSEN LAW FIRM, P. A.
Nov 11, 2025, 13:48 ET CLASS ACTION REMINDER: Berger Montague Advises MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors to Inquire About a Securities Fraud Lawsuit by December 15, 2025
Berger Montague PC announces a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake" or the "Company") on behalf of investors who purchased MoonLake shares during the period of March 10, 2024 through September 29, 2025
More news about: Berger Montague
Nov 11, 2025, 09:27 ET MLTX SHAREHOLDER NOTICE: MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman
class action, styled Bridgewood v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08500 (S.D.N.Y), has been filed after MoonLake (NASDAQ: MLTX) announced disastrous Phase 3 trial results for its only product candidate (sonelokimab, or "SLK"), its highly anticipated treatment for patients with
More news about: Hagens Berman Sobol Shapiro LLP
Nov 11, 2025, 08:45 ET Levi & Korsinsky Reminds MoonLake Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 15, 2025 - MLTX
2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) of a class action securities lawsuit.
More news about: Levi & Korsinsky, LLP
Nov 11, 2025, 04:25 ET MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX
MLTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of MLTX during the class period listed are
More news about: DJS Law Group LLP
Nov 11, 2025, 04:14 ET MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm
MLTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange
More news about: The Schall Law Firm
Nov 10, 2025, 08:45 ET MoonLake Immunotherapeutics Class Action: The Gross Law Firm Reminds MoonLake Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 15, 2025 - MLTX
Nov. 10, 2025 The Gross Law Firm issues the following notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX).
More news about: The Gross Law Firm
Nov 08, 2025, 01:12 ET DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics
LLP, a leading national securities law firm, is investigating potential claims against Reuters Research Inc. ("MoonLake" or the "Company") (NASDAQ: MLTX) and reminds investors of the December 15, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been
More news about: Faruqi & Faruqi, LLP
Nov 07, 2025, 23:59 ET MLTX INVESTOR DEADLINE: MoonLake Immunotherapeutics Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
v. MoonLake Immunotherapeutics, No. 25-cv-08612 (S.D.N.Y.) – seeks to represent purchasers or acquirers of MoonLake Immunotherapeutics (NASDAQ: MLTX) common stock and charges MoonLake and certain of MoonLake's executives with violations of the Securities Exchange Act of 1934.
More news about: Robbins Geller Rudman & Dowd LLP
Nov 07, 2025, 19:54 ET MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
MLTX) have opportunity to lead the securities fraud class action lawsuit.
More news about: The Law Offices of Frank R. Cruz, Los Angeles
Nov 07, 2025, 18:00 ET MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline.
More news about: THE ROSEN LAW FIRM, P. A.
Nov 07, 2025, 16:00 ET Levi & Korsinsky Reminds MoonLake Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 15, 2025 - MLTX
2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) of a class action securities lawsuit.
More news about: Levi & Korsinsky, LLP
Nov 07, 2025, 03:06 ET MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm
MLTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange
More news about: The Schall Law Firm
Nov 07, 2025, 02:49 ET MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX
MLTX ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of MLTX during the class period listed are
More news about: DJS Law Group LLP
Nov 06, 2025, 16:28 ET MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman
MLTX Investors with Losses Encouraged to Contact Hagens Berman SAN FRANCISCO, Nov. 6, 2025 /PRNewswire/ -- A securities class action, styled Bridgewood
More news about: Hagens Berman Sobol Shapiro LLP
Nov 06, 2025, 08:45 ET The Gross Law Firm Notifies Shareholders of MoonLake Immunotherapeutics(MLTX) of a Class Action Lawsuit and an Upcoming Deadline
Nov. 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX).
More news about: The Gross Law Firm
Nov 04, 2025, 15:26 ET MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
MLTX). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN MOONLAKE IMMUNOTHERAPEUTICS (MLTX), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE DECEMBER 15, 2025 (LEAD
More news about: Law Offices of Howard G. Smith